132 related articles for article (PubMed ID: 11273779)
1. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein.
Wu X; He Y; Falo LD; Hui KM; Huang L
Mol Ther; 2001 Mar; 3(3):368-74. PubMed ID: 11273779
[TBL] [Abstract][Full Text] [Related]
2. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
4. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
[TBL] [Abstract][Full Text] [Related]
6. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
[TBL] [Abstract][Full Text] [Related]
7. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus.
Griffith TS; Broghammer EL
Mol Ther; 2001 Sep; 4(3):257-66. PubMed ID: 11545617
[TBL] [Abstract][Full Text] [Related]
8. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Liu J; Fang B
Int J Oncol; 2003 Jun; 22(6):1241-5. PubMed ID: 12738989
[TBL] [Abstract][Full Text] [Related]
9. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
10. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells.
Lin T; Huang X; Gu J; Zhang L; Roth JA; Xiong M; Curley SA; Yu Y; Hunt KK; Fang B
Oncogene; 2002 Nov; 21(52):8020-8. PubMed ID: 12439752
[TBL] [Abstract][Full Text] [Related]
11. Induction of potent TRAIL-mediated tumoricidal activity by hFLEX/Furin/TRAIL recombinant DNA construct.
Wu X; Hui KM
Mol Ther; 2004 May; 9(5):674-81. PubMed ID: 15120328
[TBL] [Abstract][Full Text] [Related]
12. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
14. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
[TBL] [Abstract][Full Text] [Related]
15. The secretable form of trimeric TRAIL, a potent inducer of apoptosis.
Kim MH; Billiar TR; Seol DW
Biochem Biophys Res Commun; 2004 Sep; 321(4):930-5. PubMed ID: 15358116
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice.
Shi J; Zheng D; Liu Y; Sham MH; Tam P; Farzaneh F; Xu R
Cancer Res; 2005 Mar; 65(5):1687-92. PubMed ID: 15753363
[TBL] [Abstract][Full Text] [Related]
17. [Expression of TRAIL(114-281) mediated by adeno-associated virus and its tumoricidal activity].
Ma H; Liu YX; Liu SL; Xu RA; Zheng DX
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1635-41. PubMed ID: 15569460
[TBL] [Abstract][Full Text] [Related]
18. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
Bernt KM; Ni S; Tieu AT; Lieber A
Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
[TBL] [Abstract][Full Text] [Related]
19. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression.
Mohr A; Henderson G; Dudus L; Herr I; Kuerschner T; Debatin KM; Weiher H; Fisher KJ; Zwacka RM
Gene Ther; 2004 Mar; 11(6):534-43. PubMed ID: 14999225
[TBL] [Abstract][Full Text] [Related]
20. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins.
Hu B; Zhu H; Qiu S; Su Y; Ling W; Xiao W; Qi Y
Biochem Biophys Res Commun; 2004 Dec; 325(4):1153-62. PubMed ID: 15555548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]